Retatrutide by Condition
Indications being studied — obesity, MASH, diabetes, sleep apnea, heart disease.
Retatrutide's TRIUMPH Phase 3 program spans far more than obesity. Eli Lilly is running registration trials across MASH, type 2 diabetes, sleep apnea, knee osteoarthritis, and cardiovascular outcomes. Here's what's been published per indication — and what's still pending.
Related topic hubs
- Trials & FDA — TRIUMPH program by indication
- Retatrutide — Retatrutide drug overview
- Safety — Condition-specific safety notes
TRIUMPH program by indication
| Indication | Trial | Status | Deep dive |
|---|---|---|---|
| Obesity (pivotal) | TRIUMPH-1 | Active — results expected 2026 | Trials tracker |
| Obesity in type 2 diabetes | TRIUMPH-2 | Active — mid-2026 | Retatrutide for T2D |
| Obesity in cardiovascular disease | TRIUMPH-3 | Active — 2026 | Heart health |
| Knee osteoarthritis | TRIUMPH-4 (N=445, 68 wks) | Complete — 28.7% weight loss, 74–76% pain reduction | TRIUMPH-4 results |
| Cardiovascular / renal outcomes | TRIUMPH-5 | Recruiting — multi-year MACE endpoints | Heart health |
| Weight maintenance | TRIUMPH-6 (N=643) | Active, no longer recruiting | — |
| MASLD / MASH (fatty liver) | TRIUMPH-MASLD | Ongoing — Phase 2 sub-study showed 81–86% liver fat reduction | Fatty liver deep dive |
| Obstructive sleep apnea | Nested sub-study in TRIUMPH-1/-2 | Awaiting parent trial readout | Sleep apnea |
By population
- Retatrutide for women — PCOS, bone density, cycle effects, contraception.
- Retatrutide for type 2 diabetes — HbA1c and weight loss data from the Phase 2 T2D trial.
- Cardiovascular effects — blood pressure, lipids, MACE outlook.
Total TRIUMPH Phase 3 enrollment is approximately 5,800 participants. Every number above is sourced in the underlying article pages.
All conditions articles
5 articles
Retatrutide and Fatty Liver Disease (MASLD/MASH)
Retatrutide produced up to 82.4% liver fat reduction in Phase 2 — among the strongest results for any drug in development for MASLD/MASH.
Updated February 2026
Retatrutide and Heart Health (Cardiovascular Effects)
Early data shows improvements in blood pressure, lipids, and inflammation. Dedicated cardiovascular outcomes trials are underway.
Updated February 2026
Retatrutide and Sleep Apnea (Obstructive Sleep Apnea)
No retatrutide OSA data yet, but the TRIUMPH-1 nested sub-study and tirzepatide's precedent point to substantial potential.
Updated February 2026
Retatrutide for Type 2 Diabetes
Retatrutide's Phase 2 T2D data showed HbA1c reductions of -2.02% and weight loss of -16.94% — with the TRANSCEND Phase 3 program underway.
Updated February 2026
Retatrutide for Women: What the Clinical Data Shows
What women need to know about retatrutide — side effects by sex, birth control interactions, fertility, hair loss, PCOS potential, and body composition.
Updated March 2026